Lindsay Bealor Greenleaf discusses the administration’s Part B drug International Pricing Index model with Fierce Healthcare
"Besides the notion of tying drug prices to what's going on in other countries, the other big issue in today's announcement is: How is all of this going to impact the independent practices?" Greenleaf said.
[el-text]
Written by Paige Minemyer
***excerpt***
“Besides the notion of tying drug prices to what’s going on in other countries, the other big issue in today’s announcement is: How is all of this going to impact the independent practices?” Greenleaf said.
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.